SUPPORT US
CLINICAL TRIALS
FOLLOW OUR RESEARCH
RESEARCH NEWS
2018 Highlights
Projects
Clinical Trials
samples received
Allied Health
Researchers
Even modest therapeutic advances that delay disease onset and
progression could significantly reduce the burden of the disease
on patients and the level of care required.
to gluten. For people with coeliac disease, even small amounts of gluten can damage the
lining of the small intestine (bowel). We’re undertaking research initiatives that will help
discover new ways to diagnose, treat, and manage Coeliac Disease.
in childhood. Individuals with TS make involuntary movements
and vocalisations (known as tics), which may be painful,
embarassing, and functionally impairing.
that enable us to move, speak, breath, and swallow slowly fail to work normally.
Research is sorely needed to understand and alter the progression of this condition.
Run for WMR in the Bridge to Brisbane 2019
Gather your friends, family and workmates together on Sunday 25th August for a scenic 5 km or 10km’s of fun and help to
ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2® in Patients With Coeliac Disease
US Biotechnology company ImmusanT, Inc.
has discontinued the Phase 2 global study for its lead candidate, Nexvax2®, intended as a treatment for coeliac disease.
Run for WMR in the Bridge to Brisbane 2019
Gather your friends, family and workmates together on Sunday 25th August for a scenic 5 km or 10km’s of fun and help to raise much-needed funds for investment in research and clinical trials at Wesley Medical Research. When you support Wesley Medical Research and raise a minimum of $250 and
ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2® in Patients With Coeliac Disease
US Biotechnology company ImmusanT, Inc.
has discontinued the Phase 2 global study for its lead candidate, Nexvax2®, intended as a treatment for coeliac disease.
Key Partners
Our key partners help us deliver the very best in research and help with the fight against deadly disease.
